Immunocore
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies.
Total raised
€251M
€250,813,171
Funding rounds
2
Investors
2
distinct backers
Active since
2021-01
latest 2021-02
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood18
base rate 45% for Debt
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood20
base rate 12% (2+ rounds)
- ▲ €100M+ raised
- ▲ 18y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-02-05 | Debt | €189M | Oxford Finance LLC | View deal → |
| 2021-01-13 | Series C | €62M | BlackRock | View deal → |